CN118415999A - 可注射组合物、包含其的药物制剂以及制备该组合物的方法 - Google Patents

可注射组合物、包含其的药物制剂以及制备该组合物的方法 Download PDF

Info

Publication number
CN118415999A
CN118415999A CN202311609051.XA CN202311609051A CN118415999A CN 118415999 A CN118415999 A CN 118415999A CN 202311609051 A CN202311609051 A CN 202311609051A CN 118415999 A CN118415999 A CN 118415999A
Authority
CN
China
Prior art keywords
injectable composition
albumin
sbe
injectable
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311609051.XA
Other languages
English (en)
Chinese (zh)
Inventor
金爱梨
尹祯敏
约翰·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankanik Treatment Co ltd
Jeil Pharmaceutical Co Ltd
Original Assignee
Ankanik Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankanik Treatment Co ltd filed Critical Ankanik Treatment Co ltd
Publication of CN118415999A publication Critical patent/CN118415999A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202311609051.XA 2023-02-01 2023-11-29 可注射组合物、包含其的药物制剂以及制备该组合物的方法 Pending CN118415999A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2023-0013947 2023-02-01
KR20230013947 2023-02-01

Publications (1)

Publication Number Publication Date
CN118415999A true CN118415999A (zh) 2024-08-02

Family

ID=92024104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311609051.XA Pending CN118415999A (zh) 2023-02-01 2023-11-29 可注射组合物、包含其的药物制剂以及制备该组合物的方法

Country Status (15)

Country Link
EP (1) EP4658244A1 (https=)
JP (1) JP2026505092A (https=)
KR (1) KR20240121186A (https=)
CN (1) CN118415999A (https=)
AR (1) AR131668A1 (https=)
AU (1) AU2024215883A1 (https=)
CL (1) CL2025002270A1 (https=)
CO (1) CO2025011347A2 (https=)
DO (1) DOP2025000185A (https=)
IL (1) IL322431A (https=)
JO (1) JOP20250189A1 (https=)
MX (1) MX2025008735A (https=)
PE (1) PE20252396A1 (https=)
TW (1) TW202432120A (https=)
WO (1) WO2024161316A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218800A1 (zh) * 2024-04-19 2025-10-23 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
AR051041A1 (es) * 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101777971B1 (ko) * 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218800A1 (zh) * 2024-04-19 2025-10-23 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
AR131668A1 (es) 2025-04-16
CO2025011347A2 (es) 2025-09-18
IL322431A (en) 2025-09-01
KR20240121186A (ko) 2024-08-08
AU2024215883A1 (en) 2025-07-31
JP2026505092A (ja) 2026-02-10
MX2025008735A (es) 2025-11-03
DOP2025000185A (es) 2026-02-15
EP4658244A1 (en) 2025-12-10
CL2025002270A1 (es) 2025-10-03
TW202432120A (zh) 2024-08-16
JOP20250189A1 (ar) 2025-07-28
PE20252396A1 (es) 2025-10-10
WO2024161316A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
ES2286835T3 (es) Composicion farmaceutica.
US10328153B2 (en) Rifaximin complexes
JP6612200B2 (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
US7713548B2 (en) Amorphous solid dispersions
CN110876259B (zh) 注射用组合物
KR20080046673A (ko) 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
KR20230034207A (ko) 경구용 의약 조성물 및 그 제조 방법
CN118415999A (zh) 可注射组合物、包含其的药物制剂以及制备该组合物的方法
ZA200409237B (en) Immediate release pharmaceutical formulation.
KR102222774B1 (ko) 에독사반을 포함하는 약학적 제제 및 이의 제조방법
HK40111340A (zh) 可注射组合物、包含其的药物制剂以及制备该组合物的方法
US9751840B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
JPH0343251B2 (https=)
CN108289840A (zh) 用于静脉内注射Danirixin的制剂
KR20230097513A (ko) 타크로리무스를 포함하는 안정성이 개선된 약제학적 조성물
CN117281813A (zh) 一种瑞马唑仑的药物组合物
HK40025124B (zh) 注射用组合物
HK40048981B (zh) κ阿片受体激动剂的口服配制品
HK40025124A (en) Composition for injection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111340

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20260213

Address after: Seoul, South Kerean

Applicant after: Ankanik Treatment Co.,Ltd.

Country or region after: Republic of Korea

Applicant after: JE IL PHARMACEUTICAL Co.,Ltd.

Address before: Seoul, South Kerean

Applicant before: Ankanik Treatment Co.,Ltd.

Country or region before: Republic of Korea

TA01 Transfer of patent application right